SCHEMBL3528072

SCHEMBL3528072

Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc5ccccc45)cc3)c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 19/20 1.00
FLT1 P17948 6/20 0.72
ROCK2 O75116 5/20 0.72
MAP4K4 O95819 5/20 0.72
LCK P06239 5/20 0.72
FGFR1 P11362 5/20 0.72
AXL P30530 5/20 0.72
FLT3 P36888 5/20 0.72
CSNK1A1 P48729 5/20 0.72
CSNK1D P48730 5/20 0.72
CSNK1G2 P78368 5/20 0.72
MAP4K2 Q12851 5/20 0.72
ROCK1 Q13464 5/20 0.72
CAMK2B Q13554 5/20 0.72
NTRK2 Q16620 5/20 0.72
TAOK1 Q7L7X3 5/20 0.72
HIPK4 Q8NE63 5/20 0.72
AURKB Q96GD4 5/20 0.72
MAP4K5 Q9Y4K4 5/20 0.72
PLK4 O00444 4/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3530946 0.86 KDR (1.00) KDRFLT1ROCK2MAP4K4LCK
SCHEMBL3528431 0.86 KDR (0.78) KDRFLT1ROCK2MAP4K4LCK
SCHEMBL3535254 0.86 KDR (1.00) KDRFLT1ROCK2MAP4K4LCK
SCHEMBL3531454 0.85 KDR (1.00) KDRFLT1ROCK2MAP4K4LCK
SCHEMBL3533717 0.83 KDR (1.00) KDRFLT1ROCK2MAP4K4LCK
SCHEMBL3530439 0.81 KDR (1.00) KDRFLT1ROCK2MAP4K4LCK
SCHEMBL3530438 0.81 KDR (0.81) KDRFLT1ROCK2MAP4K4LCK
SCHEMBL3531696 0.81 KDR (1.00) KDRFLT1ROCK2MAP4K4LCK
SCHEMBL3527915 0.80 KDR (1.00) KDRFLT1ROCK2MAP4K4LCK
SCHEMBL3529291 0.80 KDR (1.00) KDRFLT1ROCK2MAP4K4LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 US disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 US disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 US disclosed
EP-1648905-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS Abbott Laboratories (US) 2006-04-26 EP disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 US disclosed
WO-2005010009-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK KDR 494/4885FLT1 613/4885ROCK2 455/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885FLT1 613/4885ROCK2 455/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885FLT1 613/4885ROCK2 455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.